Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-kappa antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus[1][2].
Molecular Weight:
(146 kDa)
Purity:
98.32
CAS Number:
[2210314-30-8]
Target:
Complement System
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
